

Revision date 07-Dec-2021

Version 3

Page 1/12

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name

Pfizer-BioNTech COVID-19 Vaccine

Product Code(s)

PF00092

Form

nanoform

Synonyms

Comirnaty; PF-07302048 containing PF-07305885 (BNT162b2); CorVAC Containing PF-07305885 (BNT162b2); CoVVAC Containing PF-07305885 (BNT162b2); COVID

Vaccine Containing PF-07305885 (BNT162b2); COVID-19 Vaccine Containing

PF-07305885 (BNT162b2)

Trade Name: Compound Number Not applicable

Item Code

PF-07302048 H000022941: H000023057;H000024547: H000024742

Chemical Family:

Lipid Nanoparticles containing PF-07305885 (BNT162b2) and Lipids

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use

Pharmaceutical product

1.3. Details of the supplier of the safety data sheet

Pfizer Inc 235 East 42nd Street New York, New York 10017 1-800-879-3477 Pfizer Ireland Pharmaceuticals

OSG Building

Ringaskiddy, Co. Cork.

Ireland

+353 21 4378701

1.4. Emergency telephone number

Emergency Telephone

E-mail address

Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

pfizer-MSDS@pfizer.com

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous

2.2. Label elements

Signal word

Not classified

Hazard statements

Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients

(see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless

of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

PER NOTESTING AS BELOW

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances							
Substances		Not applicable		THETE D		MULTIPYIN	WEES TOKIC
3.2 Mixtures	P = Propri	etary Su	bstance	NOT TOSTED AGAWST REGULATIONS	NOT TESTED	TO AQUATION - NOT TESTE	LLIFE
Hazardous Chemical name	Weight-%	REACH Registration Number	EC NO (IDEATHYER NUMBER ANY)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
POTASSIUM CHLORIDE 7447-40-7	<1		231-211-8	Acute Tox 5 (H303)	Not Listed	No data available	No data available
NonHazardous Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water 7732-18-5	*		231-791-2	No data available	Not Listed	No data available	No data available
Sucrose 57-50-1	< 10		200-334-9	No data available	Not Listed	No data available	No data available
SODIUM CHLORIDE 7647-14-5	< 10		231-598-3	No data available	Not Listed	No data available	No data available
ALC-0315 2036272-55-4	< 2		Not Listed	No data available	Not Listed	No data available	No data available
Potassium phosphate 7778-77-0	< 1		231-913-4	No data available	Not Listed	No data available	No data available
PF-07305885 -	<1		Not Listed	No data available	Not Listed	No data available	No data available
PF-07302048 -	< 1		Not Listed	No data available	Not Listed	No data available	No data available
Disodium phosphate dihydrate 10028-24-7	< 1		Not Listed	No data available	Not Listed	No data available	No data available
Cholesterol 57-88-5	< 1		200-353-2	No data available	Not Listed	No data available	No data available
ALC-0159 1849616-42-7	< 1		Not Listed	No data available	Not Listed	No data available	No data available
1,2-Distearoyl-sn-glyc ero-3-phosphocholine 816-94-4			212-440-2	No data available	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

		NOT TESTED	NOT TESTED	NOT TEST ED	NOT TESTED
Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Sucrose 57-50-1	29700	No data available	No data available	Tro data arramana	No data available
SODIUM CHLORIDE 7647-14-5	3000	10000	No data available	No data available	No data available
Potassium phosphate 7778-77-0	3200	No data available	0.83	No data available	No data available
POTASSIUM CHLORIDE 7447-40-7	3020	No data available		No data available	No data available
Cholesterol 57-88-5	No data available	2000	No data available	No data available	No data available

Additional information

CONTRIDICTS

SECTION 2.

- Not Assigned

* Proprietary

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as

a trade secret.

PROTECTED AS PROPRIETORY SUBSTANCE UNDER CONFIDENTIAL BUSINESS INFORMATION (CBI)

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation Remove to fresh air. Seek immediate medical attention/advice.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a physician.

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical CLASSED + STATED
AS A CHEMICAL

Fine particles (such as mists) may fuel fires/explosions.

DEFINED AS A HAZARDOUS CHEMICAL UNDER SECTION Z HSNO ACT 1996 ILAZARDOUS SUBSTANCE

Hazardous combustion products

Formation of toxic gases is possible during heating or fire. DE FINITION

5.3. Advice for firefighters

Special protective equipment for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions

Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

For emergency responders

Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions

taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Methods for cleaning up Prevent further leakage or spillage if safe to do so.

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean

spill area thoroughly.

Prevention of secondary hazards

Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections

See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Restrict access to work area. A change area to facilitate 'good laboratory/manufacturing' decontamination practices is recommended. Additional controls (based on risk assessment) should be implemented where open handling is required. Use enclosed manufacturing processing strategies. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions

Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s)

Vaccine.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Revision date 07-Dec-2021

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Sucrose

10 mg/m³ **ACGIH TLV** 10.0 mg/m³ Bulgaria 10 mg/m³ Estonia 10 mg/m³ France 10 mg/m³ Ireland STEL: 20 mg/m3 5 mg/m³ Latvia 10 mg/m³ Spain

15 mg/m³ **OSHA PEL** 5 mg/m³

(vacated) TWA: 15 mg/m3 total dust (vacated) TWA: 5 mg/m3 respirable fraction

TWA: 10 mg/m³ United Kingdom STEL: 20 mg/m3

SODIUM CHLORIDE

5 mg/m³ Latvia MAC: 5 mg/m³ Russia

Potassium phosphate

MAC: 10 mg/m3 Russia

POTASSIUM CHLORIDE 5.0 mg/m³ Bulgaria 5 mg/m³ Latvia MAC: 5 mg/m3 Russia

(OEB) Statement:

RISIZ ASSESMENT REQUIREMENTS MANDATORY UNDER MZHSWAACT 2015

Pfizer Occupational Exposure Band The Vaccines Occupational Exposure Band (V-OEB) is a classification that has been assigned to biotechnology-based vaccines and antigen components. Risk assessments should be performed to assess potential exposures and determine appropriate controls. The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

SODIUM CHLORIDE

OEB 1 (control exposure to the range of 1000ug/m3 to 3000ug/m3) Pfizer Occupational Exposure Band (OEB):

ALC-0315

OEB 3 - Contact Hazards Unknown (control exposure to the range of 10ug/m3 to < Pfizer Occupational Exposure Band (OEB): 100ug/m³)

POTASSIUM CHLORIDE

OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³) Pfizer Occupational Exposure Band (OEB):

PF-07305885

Pfizer Occupational Exposure V-OEB

Band (OEB):

PF-07302048

Pfizer Occupational Exposure

Band (OEB):

ALC-0159 Pfizer Occupational Exposure

Band (OEB):

V-OEB


OEB 3 - Contact Hazards Unknown (control exposure to the range of 10ug/m3 to < 100ug/m³)

8.2. Exposure controls

Release prevention and exposure protection measures should be established for any **Engineering controls**

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 07-Dec-2021

Page 6/12 Version 3



activities involving this material, as determined by a risk assessment conducted using appropriate Occupational Hygiene Risk Assessment tools. The containment level required for the activity should be based on the conclusions of the risk assessment. Where warranted, engineering controls, such as biosafety cabinets, should be applied as the primary means to control exposures.

Environmental exposure controls

No information available.

Personal protective equipment

Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Eye/face protection

Wear safety glasses as minimum protection (goggles recommended). (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Wear impervious gloves, (e.g. Nitrile, etc.) to prevent skin contact. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Wear impervious disposable protective clothing when handling this compound. Full body protection is recommended (scale dependent). (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

If operating and handling conditions result in airborne exposure, wear an appropriate respirator with a protection factor sufficient to control exposures (e.g. particulate cartridge with a full face respirator. P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state

Color

Odor

Odor threshold

Molecular formula

Molecular weight

Property

pН

Melting point / freezing point

Boiling point / boiling range

Flash point

Evaporation rate

Flammability (solid, gas)

Flammability Limit in Air

Upper flammability limit:

Lower flammability limit:

Vapor pressure

Vapor density Relative density Water solubility Liquid

milky white

No information available.

No information available

Mixture

Mixture

<u>Values</u>

7.4

No data available

No information available

No data available

NO TESTING

Product Name Pfizer-BioNTech COVID-19 Vaccine

Revision date 07-Dec-2021

Page 7/12 Version 3

Solubility(ies)

Partition coefficient

Autoignition temperature

Decomposition temperature

Kinematic viscosity

Dynamic viscosity

Particle characteristics

Particle Size

Particle Size Distribution

Explosive properties

No data available No data available

No data available

No data available

No data available

No data available

No information available

No information available

No information available

NO TESTING UNDERTAKEN

<u> 9.2. Other information</u>

No information available

🔾 9.2.1. Information with regard to physical hazard classes No information available

9.2.2. Other safety characteristics

No information available

NO TESTING UNDERTAKEN

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity

No data available.

10.2. Chemical stability Stability

Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available. Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid

Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep

away from heat sources and electrostatic discharge.

CLASSED AS HAZARDOUS UNDER HISTO ACT - INTERPNETATION

10.5. Incompatible materials

Incompatible materials

As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

NOT TESTED

General Information:

Short term

Toxicological properties have not been thoroughly investigated. The following information is

available for the individual ingredients.

In the event of accidental injection, an allergic reaction may occur. If an allergic reaction

occurs, the worker should be removed to the nearest emergency room and the appropriate

therapy instituted.

Known Clinical Effects:

Based on clinical trials in humans, possible adverse effects following intravenous exposure to this compound may include: injection site pain, muscle pain, headache, fever, chills, tiredness, joint pain, abnormal redness of skin (erythema), and sleep disturbances. Serious

allergic reactions, including anaphylaxis, have been reported.

Acute Toxicity: (Species, Route, End Point, Dose)

Sucrose

Rat Oral LD 50 29,700 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

POTASSIUM CHLORIDE

Rat Oral LD50 3020 mg/kg

Potassium phosphate

Rat Oral LD50 3200 mg/kg

NA = NOT ASSIGNED

Rabbit Dermai LC50 > 4640) mg/кg			
Chemical name	Oral LD50	Dermal LD50	Inhalation LC50	
Water > 90 mL/kg (Rat)		NĀ	NA	
Sucrose	= 29700 mg/kg (Rat)	NA	NA.	
SODIUM CHLORIDE	= 3 g/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat)1 h	
Potassium phosphate	= 3200 mg/kg (Rat)	NA	> 0.83 mg/L (Rat)4 h	
POTASSIUM CHLORIDE	= 2600 mg/kg (Rat)	NA	NĀ	
Cholesterol		> 2000 mg/kg (Rat)	- NA	

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

POTASSIUM CHLORIDE

Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

PF-07302048

4 Week(s) Rat Intramuscular * 10 μg LOAEL Skin, Blood forming organs, Blood, Skeletal muscle, Lymphoid tissue, Spleen **Repeated Dose Toxicity Comments: PF-07302048:** * Doses were administered once a week.

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

PF-07305885

Fertility & Embryonic Development - Females Rat Intramuscular 30 µg NOAEL No effects at maximum dose, Not teratogenic

Potassium phosphate

Reproductive & Fertility Rat No route specified 282 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus Reproductive & Fertility Mouse No route specified 320 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Potassium phosphate

Bacterial Mutagenicity (Ames) Salmonella

Negative

Carcinogenicity

Cholesterol

See below

Group 3 (Not Classifiable)

Data for the Drug Product

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 07-Dec-2021

Page 9 / 12 Version 3

Reproduction & Development Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Fertility & Embryonic Development - Females Rat Intramuscular

N/A

Not specified

No effects at maximum dose

* 11.2. Information on other hazards

*11.2.1. Endocrine disrupting properties

Endocrine disrupting properties

No information available.

NOT TESTED

11.2.2. Other information

Other adverse effects

No information available.

NOT TESTED

Section 12: ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been investigated. Releases to the environment should

be avoided. ENVIRON MENTAL HAZARD

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

POTASSIUM CHLORIDE

Gambusia affinis (Mosquitofish) LC50 96 hours 920 mg/L

Lepomis macrochirus (Bluegill Sunfish) LC50 96 hours 2010 mg/L

Daphnia Magna (Water Flea) EC50 48 hours 825 mg/L

Scenedesmus subspicatus (Green Alga) EC50 72 hours 2500 mg/L

12.2. Persistence and degradability

Persistence and degradability

No information available.

🖊 12.3. Bioaccumulative potential

Bioaccumulation

No information available.

NOT TESTED

12.4. Mobility in soil

Mobility in soil

No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment	
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does	
	not apply	
Potassium phosphate	The substance is not PBT / vPvB PBT assessment does	
·	not apply	
POTASSIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does	
7	not apply	
Cholesterol	The substance is not PBT / vPvB	

12.6. Endocrine disrupting properties

* -----

Endocrine disrupting properties

No information available.

*

12.7. Other adverse effects
No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Not Listed - EMERGENCY PLANNING ACT Not Listed - DENOTES IF CANCER FORMING CERCLA/SARA Section 313 de minimus % California Proposition 65 Present - TOXIC SUBSTANCES CONTROL TSCA 231-791-2 EUROPEAN INVENTORY CHEMICAL SUBSTANCES **EINECS** Present - AUST INVENTORY OF CHEMICAL SUBST AICS Sucrose Not Listed - NOT TESTED CERCLA/SARA Section 313 de minimus % Not Listed - NOT TESTED California Proposition 65 Present — CBI 200-334-9 - 7 DIGIT REGISTRATION NUMBER ONLY TSCA Present - CBI - PRESENT AS A UST ITEM ONLY **EINECS** AICS SODIUM CHLORIDE CERCLA/SARA Section 313 de minimus % Not Listed -Not Listed ----California Proposition 65 Present • TSCA 231-598-3 **EINECS** Present -AICS ALC-0315 Not Listed -CERCLA/SARA Section 313 de minimus % Not Listed ----California Proposition 65 Not Listed ---- EINECS Potassium phosphate Not Listed -CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 **TSCA** Present -231-913-4 **EINECS**

PF00092

NOTES - CB1 = CONFIDENTIAL BUSINESS INFORMATION

A CLAIM TO US ENLIRONMENTAL PROTECTION AGENCY

TO HAVE A "PROPRIETORY SUBSTANCE" AS CONFIDENTIAL

TO PROTECT INTELECTUAL PROPRETY RIGHTS

HENCE NOT TESTED OR REGULATED BY THE ABOUT

REGULATORS OR GOVERNING BODIES IN COUNTRIES

LISTED ABOUK - THAT IS - NOT TESTED

NOTE:

- AICS	Present	- cBl
POTASSIUM CHLORIDE	Maddistant	
CERCLA/SARA Section 313 de minimus %	Not Listed —	- N7
California Proposition 65	Not Listed -	$ \sqrt{7}$.
TSCA	Present -	- CB1
EINECS	231-211-8	7 DIGIT
AICS	Present -	- CBISSED POISEN
Standard for Uniform Scheduling of Medicines	and Schedule 4	CLASSED POISON
Poisons (SUSMP)		
PF-07305885		
CERCLA/SARA Section 313 de minimus %	Not Listed -	
— California Proposition 65	Not Listed -	
EINECS	Not Listed -	- NT
PF-07302048		
— CERCLA/SARA Section 313 de minimus %	Not Listed -	- NT
California Proposition 65	Not Listed -	- NOT
EINECS	Not Listed -	- NT
Disodium phosphate dihydrate	-	•
CERCLA/SARA Section 313 de minimus %	Not Listed -	- NT
California Proposition 65	Not Listed —	- NT
— EINECS	Not Listed — Not Listed —	- 101
- AICS	Present -	<i>(CIZ</i>)
Standard for Uniform Scheduling of Medicines		CLASSED POISON
Poisons (SUSMP)		
Cholesterol		
CERCLA/SARA Section 313 de minimus %	Not Listed -	- NT
California Proposition 65	Not Listed — Present	- 101
TSCA	Present -	- CB1
EINECS	200-353-2	7 PIGT
AICS	Present -	- CBI
Standard for Uniform Scheduling of Medicines		CLASSED POISON
Poisons (SUSMP)		
ALC-0159		
— CERCLA/SARA Section 313 de minimus %	Not Listed -	- NT
California Proposition 65	Not Listed —	- 07
EINECS	Not Listed -	- 121
1,2-Distearoyl-sn-glycero-3-phosphocholine		No C
CERCLA/SARA Section 313 de minimus %	Not Listed -	- NT
California Proposition 65	Not Listed —	- NT - NT 7 0161T
EINECS	212-440-2	7 01611
LINEOG	M	
France		TALL TOT ASSILATED
Occupational Illnesses (R-463-3, France)		NA = NOT ASSIGNED
Chemical name	French RG number	Title
SODIUM CHLORIDE	RG 78	
7647-14-5		NA
1011 110		

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

RG 67

ŇΑ

Authorizations and/or restrictions on use:

POTASSIUM CHLORIDE

7447-40-7

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

CONTRADICTS ENVIRONTHENTAL PELFASE STATEMENTS SECTIONS 7.1 9 13.1

Ozone-depleting substances (ODS) regulation (EC) 1005/2009 Not applicable

Plant protection products directive (91/414/EEC)

I talle protection products all cours (c.) I was a			
Chemical name	Plant protection products directive (91/414/EEC)		
Sucrose - 57-50-1	Plant protection agent		
SODIUM CHLORIDE - 7647-14-5	Plant protection agent		

LEGEND-FOR SECTION IS . 1.

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

*

15.2. Chemical safety assessment

Chemical Safety Report

No information available

CLASSED AS UNTESTED HAZANDOUS SUBSTAUCE

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.5; H303 - May be harmful if swallowed

Data Sources:

Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision

Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection.

Updated Section 16 - Other Information.

Revision date

07-Dec-2021

Prepared By

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

NOT TESTED, CERTIFIED, DEGULATED OR LICENSED